Home › Drug Codes › J Codes › J7686 · TYVASO
Updated July 1st, 2026

TYVASO J Code: J7686

Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J7686, effective October 1, 2026: $830.383 per HCPCS billing unit, down 0.3% from $832.827. From CMS's final file.

?
Medicare Payment Limit ?
$832.827
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
Not published
CMS publishes none for Q3 2026
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
4
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg
HCPCS Added Date January 1, 2011
Manufacturer United Therapeutics
Route of Administration Oral
Generic Status Single-Source; Branded
Dosage Form Inhalant

About TYVASO

Tyvaso is a medication aligned to the HCPCS J Code: J7686 for billing, pricing, and reimbursement purposes in the United States. This Cardiology medication is administered via the oral route and manufactured by United Therapeutics.

According to CMS Drug Use Information: This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to increase your ability to exercise and improves symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
66302-0206-01 Tyvaso United Therapeutics Corporation 28 1.74 MG / 2.9 ML
66302-0206-02 Tyvaso United Therapeutics Corporation 28 1.74 MG / 2.9 ML
66302-0206-03 Tyvaso United Therapeutics Corporation 4 1.74 MG / 2.9 ML
66302-0206-04 Tyvaso United Therapeutics Corporation 4 1.74 MG / 2.9 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

TYVASO Pricing & Reimbursement

J7686 Private Payer Reimbursement
$792.76 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

TYVASO CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes.
Not on the CMS JW / JZ list

CMS does not include Tyvaso (J7686) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J7686. Wastage billing guide →

TYVASO Medically Unlikely Edits (MUE)

The most billing units of J7686 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1.74 mg. The limit is different in the office and the hospital. Use the one for your setting.

Practitioner Office
1 unit / day
= 1.74 mg per day
Hospital Outpatient
0 units / day
Not payable in this setting

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

TYVASO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Pulmonary Arterial Hypertension (PAH; WHO Group 1) Pulmonary Hypertension Associated with ILD (PH-ILD; WHO Group 3)
Drug Class
Prostacycline Vasodilator [EPC]Prostaglandins I [CS]Vasodilation [PE]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Tyvaso billing and coding guide?
Our team has not identified a manufacturer-published source of billing and coding information for TYVASO.
Are there any available Tyvaso patient assistance programs?
TYVASO patient assistance information can be found through United Therapeutics. Visit Here →
Where can I find Tyvaso prescribing information?
TYVASO prescribing information can be found at the link below: Visit Here →
Where can I find Tyvaso side effect information?
Information regarding TYVASO's side effects can be found at MedlinePlus Visit Here →
Does billing TYVASO require JZ/JW wastage modifiers?
CMS does not include TYVASO (J7686) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J7686. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to TYVASO.

J3285REMODULINInjection, treprostinil, 1 mgMultiple ManufacturersAdded January 1, 2006J1325EPOPROSTENOL SODIUMInjection, epoprostenol, 0.5 mgMultiple ManufacturersAdded January 1, 1998C9248CLEVIPREXInjection, clevidipine butyrate, 1 mgChiesi USAAdded January 1, 2009C9482SOTALOL HCLInjection, sotalol hydrochloride, 1 mgAltathera PharmaceuticalsAdded October 1, 2016J0130ABCIXIMABInjection abciximab, 10 mgAdded January 1, 1999J0153ADENOCARDInjection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)Multiple ManufacturersAdded January 1, 2015J0162EPINEPHRINE HCLInjection, epinephrine (fresenius), not therapeutically equivalent to j0165, 0.1 mgFresenius KabiAdded January 1, 2026J0163ADRENALINInjection, epinephrine in sodium chloride (endo), 0.1 mgPar Pharmaceutical, IncAdded October 1, 2025J0164EPINEPHRINE (BAXTER)Injection, epinephrine in sodium chloride (baxter), 0.1 mgBaxter HealthcareAdded October 1, 2025J0165EPINEPHRINE HCLInjection, epinephrine, not otherwise specified, 0.1 mgMultiple ManufacturersAdded July 1, 2025